Clinical-stage biopharmaceutical company Heat Biologics has signed a definitive agreement to purchase 80% stake in US-based immuno-oncology company Pelican Therapeutics.

"Kasten and Thru Pharma have announced the completion of their merger."

The acquirer company has agreed to pay $0.5m in cash upfront and issue 1.3 million shares of its common stock to the target company’s shareholders as consideration for the acquisition.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Kasten and Thru Pharma have announced the completion of their merger.

Kasten will continue to operate under the same name following the merger.

Operating as DAKOTA Life Sciences, Thru Pharma expects the merged entity will enable to offer unique and affordable prescription and over-the-counter (OTC) pharmaceutical products to the market.

See Also:

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.